ViroCarb is a science-driven biotech company focused on the development and commercialization of innovative drugs for viral infections with urgent unmet therapeutic needs. 

Our approach of blocking host cell’s processes needed for viral replication overcomes the limitations of current antiviral drug development, directed against viral-encoded targets, caused by extensive viral mutations that limit efficacy and promote drug resistance (e.g. DNA polymerase, reverse transcriptase, protease, and neuraminidase inhibitors).